1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[4-(hydroxymethyl)-3-(phenylmethyl)-2(3H)-thiazolylidene]-, [N(Z)]- manufacturers
- TDI-011536
-
- $51.00
-
2026-05-14
- CAS:2687970-96-1
- Purity: 98.35%
- Supply Ability: 10g
|
| | 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[4-(hydroxymethyl)-3-(phenylmethyl)-2(3H)-thiazolylidene]-, [N(Z)]- Basic information |
| | 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[4-(hydroxymethyl)-3-(phenylmethyl)-2(3H)-thiazolylidene]-, [N(Z)]- Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 12.30±0.40(Predicted) | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C19H16N4O2S/c24-11-14-12-26-19(23(14)10-13-5-2-1-3-6-13)22-18(25)16-9-21-17-15(16)7-4-8-20-17/h1-9,12,24H,10-11H2,(H,20,21)/b22-19- | | InChIKey | LJNPGPUDPDQGLE-QOCHGBHMSA-N | | SMILES | C(C1C=CC=CC=1)N1C(=CS/C/1=N\C(C1=CNC2=NC=CC=C12)=O)CO |
| | 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[4-(hydroxymethyl)-3-(phenylmethyl)-2(3H)-thiazolylidene]-, [N(Z)]- Usage And Synthesis |
| Description | TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration[1]. TDI-011536 (3 µM; 24 h) reduces Yap phosphorylation and (3 µM; 5 days) induces proliferation of MÜller glia in human retinal organoids[1]. Cell Proliferation Assay[1] TDI-011536 (200 mg/kg; i.p.; once) provides over 4 h of Lats inhibition in the liver, heart, and skin and reduces the amount of pYap for at least 4 h after injection in all three organs[1].
TDI-011536 (100 mg/kg; i.p.; once daily for 2 or 3 days) shows proliferative effect on cardiomyocytes[1]. | | Uses | TDI-011536 is a potent Lats kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration[1]. | | in vivo | TDI-011536 (200 mg/kg; i.p.; once) provides over 4 h of Lats inhibition in the liver, heart, and skin and reduces the amount of pYap for at least 4 h after injection in all three organs[1].
TDI-011536 (100 mg/kg; i.p.; once daily for 2 or 3 days) shows proliferative effect on cardiomyocytes[1]. | Animal Model: | Living mice (immunoblot analysis of the heart, liver, and skin immediately after injection)[1]. | | Dosage: | 200 mg/kg | | Administration: | Intraperitoneal injections; once. | | Result: | Reduced the amount of pYap for at least 4 h after injection in all three organs and the levels returned to control values within a day. |
| Animal Model: | Male 8-week-old mice (cryolesion model)[1]. | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneal injections; once daily for 2 or 3 days. | | Result: | Promoted cardiomyocytes proliferation. |
| | References | [1] Kastan NR, et al. Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2206113119. DOI:10.1073/pnas.2206113119 |
| | 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[4-(hydroxymethyl)-3-(phenylmethyl)-2(3H)-thiazolylidene]-, [N(Z)]- Preparation Products And Raw materials |
|